Clinical Trial Update: Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH

View source ↗

Summary

Clinical trial update on candesartan and candesartan/hydrochlorothiazide for essential hypertension with left ventricular hypertrophy; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension
• Left Ventricular Hypertrophy

Drugs mentioned

• Candesartan (candesartan)
• Candesartan/Hydrochlorothiazide (candesartan/hydrochlorothiazide)

Snippet

Sponsor: AstraZeneca | Conditions: Essential Hypertension, Left Ventricular Hypertrophy | Status: COMPLETED